131 related articles for article (PubMed ID: 10897069)
21. An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus.
Quinlivan M; Gershon AA; Steinberg SP; Breuer J
J Med Virol; 2005 Jan; 75(1):174-80. PubMed ID: 15543576
[TBL] [Abstract][Full Text] [Related]
22. Varicella-zoster virus gene 21: transcriptional start site and promoter region.
Cohrs RJ; Barbour M; Gilden DH
J Virol; 1998 Jan; 72(1):42-7. PubMed ID: 9420198
[TBL] [Abstract][Full Text] [Related]
23. Sequence Analysis and Comparison of the Key Genes of Domestic Live Attenuated Varicella Vaccine.
Quan YR; Chen Z; Qiu P; Cui XY; Li CG; Yuan LY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Oct; 39(5):637-642. PubMed ID: 29125105
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of Sp cellular transcription factors on viral promoter activation by varicella-zoster virus (VZV) IE62 protein.
Khalil MI; Ruyechan WT; Hay J; Arvin A
Virology; 2015 Nov; 485():47-57. PubMed ID: 26207799
[TBL] [Abstract][Full Text] [Related]
25. The transcriptional activation domain of varicella-zoster virus open reading frame 62 protein is not conserved with its herpes simplex virus homolog.
Cohen JI; Heffel D; Seidel K
J Virol; 1993 Jul; 67(7):4246-51. PubMed ID: 8389926
[TBL] [Abstract][Full Text] [Related]
26. [Characterization analysis of gM, gL genes of varicella zoster virus in six provinces of China].
Mou JJ; Qi MY; Li CS; Zheng HY; Chen M; Zhou JH; He JL; Xu WW; Xu ST; Xu XG
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Apr; 52(4):419-423. PubMed ID: 29614611
[No Abstract] [Full Text] [Related]
27. Comparison between of the attenuated BR-Oka and the wild type strain of Varicella Zoster Virus (VZV) on the DNA level.
Lim SM; Song SW; Kim SL; Jang YJ; Kim KH; Kim HJ
Arch Pharm Res; 2000 Aug; 23(4):418-23. PubMed ID: 10976594
[TBL] [Abstract][Full Text] [Related]
28. Analysis of single nucleotide polymorphism among Varicella-Zoster Virus and identification of vaccine-specific sites.
Jeon JS; Won YH; Kim IK; Ahn JH; Shin OS; Kim JH; Lee CH
Virology; 2016 Sep; 496():277-286. PubMed ID: 27376245
[TBL] [Abstract][Full Text] [Related]
29. Characterization of varicella-zoster virus-encoded ORF0 gene--comparison of parental and vaccine strains.
Koshizuka T; Ota M; Yamanishi K; Mori Y
Virology; 2010 Sep; 405(2):280-8. PubMed ID: 20598727
[TBL] [Abstract][Full Text] [Related]
30. The varicella-zoster virus (VZV) open-reading frame 29 protein acts as a modulator of a late VZV gene promoter.
Boucaud D; Yoshitake H; Hay J; Ruyechan W
J Infect Dis; 1998 Nov; 178 Suppl 1():S34-8. PubMed ID: 9852970
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.
Sauerbrei A; Eichhorn U; Gawellek S; Egerer R; Schacke M; Wutzler P
J Med Virol; 2003 Oct; 71(2):313-9. PubMed ID: 12938208
[TBL] [Abstract][Full Text] [Related]
32. Vaccine Oka variants and sequence variability in vaccine-related skin lesions.
Breuer J; Schmid DS
J Infect Dis; 2008 Mar; 197 Suppl 2():S54-7. PubMed ID: 18419409
[TBL] [Abstract][Full Text] [Related]
33. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka).
Kinchington PR; Ling P; Pensiero M; Moss B; Ruyechan WT; Hay J
J Virol; 1990 Sep; 64(9):4540-8. PubMed ID: 2166829
[TBL] [Abstract][Full Text] [Related]
34. Complete DNA sequences of two oka strain varicella-zoster virus genomes.
Tillieux SL; Halsey WS; Thomas ES; Voycik JJ; Sathe GM; Vassilev V
J Virol; 2008 Nov; 82(22):11023-44. PubMed ID: 18787000
[TBL] [Abstract][Full Text] [Related]
35. Restriction fragment differences between the genomes of the Oka varicella vaccine virus and American wild-type varicella-zoster virus.
Adams SG; Dohner DE; Gelb LD
J Med Virol; 1989 Sep; 29(1):38-45. PubMed ID: 2573686
[TBL] [Abstract][Full Text] [Related]
36. DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine.
Gomi Y; Ozaki T; Nishimura N; Narita A; Suzuki M; Ahn J; Watanabe N; Koyama N; Ushida H; Yasuda N; Nakane K; Funahashi K; Fuke I; Takamizawa A; Ishikawa T; Yamanishi K; Takahashi M
Vaccine; 2008 Oct; 26(44):5627-32. PubMed ID: 18706951
[TBL] [Abstract][Full Text] [Related]
37. Analysis of United Kingdom wild-type strains of varicella-zoster virus: differentiation from the Oka vaccine strain.
Hawrami K; Breuer J
J Med Virol; 1997 Sep; 53(1):60-2. PubMed ID: 9298733
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a thienylcarboxamide derivative that inhibits the transactivation functions of cytomegalovirus IE2 and varicella zoster virus IE62.
Majima R; Shindoh K; Yamaguchi T; Inoue N
Antiviral Res; 2017 Apr; 140():142-150. PubMed ID: 28161581
[TBL] [Abstract][Full Text] [Related]
39. Mutational analysis of varicella-zoster virus major immediate-early protein IE62.
Baudoux L; Defechereux P; Schoonbroodt S; Merville MP; Rentier B; Piette J
Nucleic Acids Res; 1995 Apr; 23(8):1341-9. PubMed ID: 7753624
[TBL] [Abstract][Full Text] [Related]
40. Nationwide distribution of varicella-zoster virus clades in China.
Xu S; Chen M; Zheng H; Wang H; Chen M; Zhou J; Shuang W; Yu P; Ma C; He J; Feng D; Zhen Z; Yan Z; Naiying M; Cui A; Wu Q; Qi M; Li C; Xu X; Xu W
BMC Infect Dis; 2016 Oct; 16(1):542. PubMed ID: 27717328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
